{"DataElement":{"publicId":"3241484","version":"1","preferredName":"Prostate Carcinoma Post Treatment Biopsy Disease Progression Type","preferredDefinition":"Text term to represent the type of treatment failure seen in a patient with prostate carcinoma based on a biopsy.","longName":"PROS_CA_BX_PROG_TP","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3241483","version":"1","preferredName":"Prostate Carcinoma Post Treatment Biopsy Disease Progression","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002_Post; occuring after._A type of study protocol designed to evaluate intervention(s) for disease treatment.Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body._Cancer that continues to grow or spread.","longName":"PROS_CA_TX_BX_PROG","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2744055","version":"1","preferredName":"Prostate Carcinoma","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002","longName":"C4863","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B8AEEC8-FDF2-03F8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-04-23","modifiedBy":"ONEDATA","dateModified":"2008-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3241481","version":"1","preferredName":"Post Treatment Study Biopsy Disease Progression","preferredDefinition":"Post; occuring after.:A type of study protocol designed to evaluate intervention(s) for disease treatment.:Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.:Cancer that continues to grow or spread.","longName":"C38008:C49656:C15189:C17747","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Treatment Study","conceptCode":"C49656","definition":"A type of study protocol designed to evaluate intervention(s) for disease treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Biopsy","conceptCode":"C15189","definition":"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4934A07-8927-D612-E040-BB89AD431178","latestVersionIndicator":"Yes","beginDate":"2011-05-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-31","modifiedBy":"ONEDATA","dateModified":"2011-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4934A07-8938-D612-E040-BB89AD431178","latestVersionIndicator":"Yes","beginDate":"2011-05-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-31","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3241474","version":"1","preferredName":"Prostate Carcinoma Post Treatment Disease Progression Type","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002_Post; occuring after._A type of study protocol designed to evaluate intervention(s) for disease treatment._Cancer that continues to grow or spread._Type; a subdivision of a particular kind of thing.","longName":"PROS_CA_TX_PROG_TP","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"12","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Distal","valueDescription":"Distal Disease Progression","ValueMeaning":{"publicId":"3241475","version":"1","preferredName":"Distal Disease Progression","longName":"3241475","preferredDefinition":"Distal; situated farthest from a point of attachment or origin, as of a limb or bone; or directed away from the midline or mesial plane of the body.: Cancer that continues to grow or spread.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Distal","conceptCode":"C25237","definition":"Situated farthest from a point of attachment or origin, as of a limb or bone; or directed away from the midline of the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4934A07-8824-D612-E040-BB89AD431178","latestVersionIndicator":"Yes","beginDate":"2011-05-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A4934A07-883D-D612-E040-BB89AD431178","beginDate":"2011-05-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-31","modifiedBy":"ONEDATA","dateModified":"2011-05-31","deletedIndicator":"No"},{"value":"Regional","valueDescription":"Regional Disease Disease Progression","ValueMeaning":{"publicId":"3241476","version":"1","preferredName":"Regional Disease Disease Progression","longName":"3241476","preferredDefinition":"A disease or condition that extends beyond the site and spreads into adjacent tissues and regional lymph nodes.\r\n: Cancer that continues to grow or spread.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Regional Disease","conceptCode":"C41844","definition":"A disease or condition that extends beyond the site and spreads into adjacent tissues and regional lymph nodes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4934A07-884A-D612-E040-BB89AD431178","latestVersionIndicator":"Yes","beginDate":"2011-05-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A4934A07-8863-D612-E040-BB89AD431178","beginDate":"2011-05-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-31","modifiedBy":"ONEDATA","dateModified":"2011-05-31","deletedIndicator":"No"},{"value":"Local","valueDescription":"Local Disease Progression","ValueMeaning":{"publicId":"3241477","version":"1","preferredName":"Local Disease Progression","longName":"3241477","preferredDefinition":"Restricted to the site of origin, without evidence of spread.: Cancer that continues to grow or spread.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Localized","conceptCode":"C14146","definition":"Restricted to the site of origin, without evidence of spread.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4934A07-8870-D612-E040-BB89AD431178","latestVersionIndicator":"Yes","beginDate":"2011-05-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A4934A07-8889-D612-E040-BB89AD431178","beginDate":"2011-05-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-31","modifiedBy":"ONEDATA","dateModified":"2011-05-31","deletedIndicator":"No"},{"value":"Biochemical","valueDescription":"Biochemical Disease Progression","ValueMeaning":{"publicId":"3241478","version":"1","preferredName":"Biochemical Disease Progression","longName":"3241478","preferredDefinition":"Biochemical; of or relating to biochemistry; involving chemical processes in living organisms.: Cancer that continues to grow or spread.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biochemical","conceptCode":"C25434","definition":"Of or relating to biochemistry; involving chemical processes in living organisms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4934A07-8896-D612-E040-BB89AD431178","latestVersionIndicator":"Yes","beginDate":"2011-05-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A4934A07-88AF-D612-E040-BB89AD431178","beginDate":"2011-05-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-31","modifiedBy":"ONEDATA","dateModified":"2011-05-31","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3241473","version":"1","preferredName":"Prostate Carcinoma Post Treatment Study Disease Progression Type","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002:Post; occuring after.:A type of study protocol designed to evaluate intervention(s) for disease treatment.:Cancer that continues to grow or spread.:Type; a subdivision of a particular kind of thing.","longName":"3241473v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Treatment Study","conceptCode":"C49656","definition":"A type of study protocol designed to evaluate intervention(s) for disease treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4934A07-87FD-D612-E040-BB89AD431178","latestVersionIndicator":"Yes","beginDate":"2011-05-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-31","modifiedBy":"ONEDATA","dateModified":"2011-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4934A07-880E-D612-E040-BB89AD431178","latestVersionIndicator":"Yes","beginDate":"2011-05-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-31","modifiedBy":"REEVESD","dateModified":"2011-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2812571","version":"1","longName":"Lombardi Cancer Center","context":"NCIP"},{"publicId":"2812605","version":"1","longName":"Lombardi New CDEs","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Reason","type":"Preferred Question Text","description":"Reason","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4934A07-8949-D612-E040-BB89AD431178","latestVersionIndicator":"Yes","beginDate":"2011-05-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-31","modifiedBy":"MAESKEB","dateModified":"2019-11-05","changeDescription":"Released CDEs as part of quarterly metrics reviews. bsm; Curated for Lombardi Cancer Center prostate cancer clinical trial; Released during draft new, retired and orphan content clean-up_11.27.18_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}